Each year, 18 million people are diagnosed with cancer.
Surgery remains the best treatment option, but survival rates are too low.
Today, hospitals use a lengthy diagnostic process called "frozen sections" that involves freezing the tissue, cutting it into thin slices and waiting on an on-call pathologist to provide an analysis using a 100+ year old method.
We’re combining our proprietary MasSpec Pen technology with cutting-edge mass spectrometry, sophisticated pattern recognition, and data analytics to transform cancer surgery.
Results in seconds
In situ analysis
without labels or agents
Helping surgeons make informed decisions
Our proprietary MasSpec Pen technology touches the tissue and extracts molecules that are diagnostic to the disease state and delivers those molecules to a mass spectrometer for analysis.
The mass spectrometer generates 1000s of signals per second that are related to the tissue of interest.
Our proprietary data analytics and AI/ML algorithms analyze the data in real-time and present a clinical risk score to the user.
Accuracy
Sensitivity
Specificity
